ulrich medical releases enhancements to spinal implant portfolio

NewsGuard 100/100 Score

ulrich medical USA, Inc. today announced the release of two important product line enhancements to their growing spinal implant portfolio of expandable cage technologies.

The first product enhancement is the introduction of a 4.0 mm osmium™ screw for the ADDplus implant which is used for vertebral body replacement in the thoracolumbar spine (T1-L5) to replace a collapsed, damaged or unstable vertebral body due to trauma or tumor. As its name suggests, the ADDplus is an expandable anterior distraction device which is innovatively designed with pre-attached, low-profile fixation plates and it is the only implant of its kind currently available on the US market. 

The second enhancement to the VBR® product lines was made to the obelisc® implant system with the release of a new short locking center screw which allows for maximum bone or bone substitute materials to be placed inside the cage for enhanced fusion. 

"Over the past 18 months, we have spent a great deal of time understanding the requirements of the US spine market and we have received valuable surgeon feedback related to our implant systems and instrumentation. As a result, we are introducing new features to our cage technologies that will allow for broader US market acceptance moving forward," said Erika Laskey, Vice President of Sales and Marketing, ulrich medical USA.

Source:

ulrich medical USA, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Advancing osteosarcoma prognosis with AI-assisted tumor cell density analysis